Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Volunteers: Asian, Non-Asian Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

NCT02059330
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg, Palbociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Sep 30, 2026, 3:07 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

NCT05298332
View directory record Official record
Conditions
Chronic Hepatitis b
Interventions
ATI-2173 50 mg
Drug
Lead sponsor
Antios Therapeutics, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Sep 30, 2026, 3:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

NCT03301181
View directory record Official record
Conditions
Healthy Volunteers: Asian, Non-Asian
Interventions
BGB-3111 (Arm A), Rifampin, BGB-3111 (Arm B), Itraconazole
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Sep 30, 2026, 3:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

NCT05543369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Elafibranor
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 30, 2026, 3:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

NCT03250598
View directory record Official record
Conditions
Healthy, Japanese, Non-Asian
Interventions
AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 30, 2026, 3:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

NCT04077879
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1617, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 30, 2026, 3:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants

NCT04145128
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG881
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 30, 2026, 3:07 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

NCT07604558
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Bretisilocin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 3:07 AM EDT